Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1. Samples disposition and testing for human papillomavirus (HPV)–related biomarkers. *Excludes samples that were too hemorrhagic or necrotic for.

Similar presentations


Presentation on theme: "Figure 1. Samples disposition and testing for human papillomavirus (HPV)–related biomarkers. *Excludes samples that were too hemorrhagic or necrotic for."— Presentation transcript:

1 Figure 1. Samples disposition and testing for human papillomavirus (HPV)–related biomarkers. *Excludes samples that were too hemorrhagic or necrotic for appropriate assessment or processing. †Includes both cancers that were HPV-DNA positive and cancers that were HPV-DNA negative but tubulin positive. ‡For E6*I mRNA, includes samples with available material that tested positive for an HPV type for which the type-specific mRNA detection assay was available. For immunohistochemistry assays, includes specimens with available material. H&E = hematoxylin and eosin; HPV = human papillomavirus; Uns. = unspecified. From: HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients J Natl Cancer Inst. 2016;108(6). doi: /jnci/djv403 J Natl Cancer Inst | © The Author Published by Oxford University Press. All rights reserved. For Permissions, please

2 Figure 2. Human papillomavirus (HPV)–attributable fractions in head and neck cancers according to positivity and/or overexpression of selected biomarkers of HPV-induced carcinogenesis. CI = 95% confidence interval; HPV = human papillomavirus; n = Number of positive cancers; N = number of tested cancers for the specified markers; Uns. = unspecified. From: HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients J Natl Cancer Inst. 2016;108(6). doi: /jnci/djv403 J Natl Cancer Inst | © The Author Published by Oxford University Press. All rights reserved. For Permissions, please

3 Figure 3. Human papillomavirus (HPV)–attributable fractions in head and neck cancers by subregion according to positivity and/or overexpression of selected biomarkers of HPV-induced carcinogenesis. *Excludes North America and Eastern-Southern Asia because of low number of cancers tested (<45). †Excludes Western Africa, Northern America, Central-Southern Asia, and South-Eastern Asia because of low number of cancers tested (<45). ‡Excludes North America, Central-Southern Asia, Eastern Asia, and Western Asia because of low number of cancers tested (<45). AF = attributable fraction; HPV = human papillomavirus. From: HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients J Natl Cancer Inst. 2016;108(6). doi: /jnci/djv403 J Natl Cancer Inst | © The Author Published by Oxford University Press. All rights reserved. For Permissions, please


Download ppt "Figure 1. Samples disposition and testing for human papillomavirus (HPV)–related biomarkers. *Excludes samples that were too hemorrhagic or necrotic for."

Similar presentations


Ads by Google